The transcriptional regulator gene E2 of the Human Papillomavirus (HPV) 16 influences the radiosensitivity of cervical keratinocytes

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Lindel, Katja ^a   Rieken, Stefan ^a   Daffinger, Sigrid ^a   Weber, Klaus J ^a   de Villiers, Ethel Michele ^b   Debus, Jürgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cervical keratinocytes; E2 gene; Human Papillomavirus; Radiosensitvity

Indexed keywords

PROTEIN P53;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; KERATINOCYTE; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; REGULATOR GENE; TRANSCRIPTIONAL REGULATOR GENE E2;

CELL LINE, TUMOR; CERVIX UTERI; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; HUMANS; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RADIATION TOLERANCE; UTERINE CERVICAL NEOPLASMS;

EID: 84868328858     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-187     Document Type: Article

References (38)

1. Zur Hausen H. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin Cancer Biol 1999, 9:405-411.
2. Spandidos DA, Dokianakis DN, Kallergi G, Aggelakis E. Molecular basis of gynecological cancer. Ann N Y Acad Sci 2000, 900:56-64.
3. Scheffner M, Romanczuk H, Munger K, Huibregtse JM, Mietz JA, Howley PM. Functions of human papillomavirus proteins. Curr Top Microbiol Immunol 1994, 186:83-99.
4. Kalantari M, Karlsen F, Kristensen G, Holm R, Hagmar B, Johansson B. Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. Int J Gynecol Pathol 1998, 17:146-153.
5. Vernon SD, Unger ER, Reeves WC. Human papillomaviruses and anogenital cancer [letter; comment]. N Engl J Med 1998, 338:921-922.
6. Desaintes C, Goyat S, Garbay S, Yaniv M, Thierry F. Papillomavirus E2 induces p53-independent apoptosis in HeLa cells. Oncogene 1999, 18:4538-4545.
7. Lindel K, de Villiers EM, Burri P, Studer U, Altermatt HJ, Greiner RH, Gruber G. Impact of viral E2-gene status on outcome after radiotherapy for patients with human papillomavirus 16-positive cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 2006, 65:760-765. Epub 2006 May 6.
8. Vernon SD, Unger ER, Miller DL, Lee DR, Reeves WC. Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. Int J Cancer 1997, 74:50-56.
9. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999, 18:7690-7700.
10. Berezutskaya E, Yu B, Morozov A, Raychaudhuri P, Bagchi S. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ 1997, 8:1277-1286.
11. Stanley MA, Browne HM, Appleby M, Minson AC. Properties of a non-tumorigenic human cervical keratinocyte cell line. Int J Cancer 1989, 43:672-676.
12. Bechtold V, Beard P, Raj K. Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA. J Virol 2003, 77:2021-2028.
13. Kersch RL, Thilly WG. Internal standards for survival: increasing the accuracy for human cell mutation assays. Mutat Res 1987, 182:83-97.
14. Schafer J, Bachtler J, Engling A, Little JB, Weber KJ, Wenz F. Suppression of apoptosis and clonogenic survival in irradiated human lymphoblasts with different TP53 status. Radiat Res 2002, 158:699-706.
15. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001, 92:805-813.
16. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 1997, 16:504-514.
17. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991, 88:5523-5527.
18. Alazawi W, Pett M, Strauss S, Moseley R, Gray J, Stanley M, Coleman N. Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. Br J Cancer 2004, 91:2063-2070.
19. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996, 10:2438-2451.
20. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992, 70:923-935.
21. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992, 70:937-948.
22. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505.
23. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248:76-79.
24. Pang E, Delic NC, Hong A, Zhang M, Rose BR, Lyons JG. Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6 *I. Int 79:860-865. Epub 2010 Nov 23.
25. Liu ZG, Zhao LN, Liu YW, Li TT, Fan DM, Chen JJ. Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents. J Mol Biol 2007, 374:334-345. Epub 2007 Sep 18.
26. Hampson L, El Hady ES, Moore JV, Kitchener H, Hampson IN. The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. FASEB J 2001, 15:1445-1447.
27. Huang RP, Fan Y, Peng A, Zeng ZL, Reed JC, Adamson ED, Boynton AL. Suppression of human fibrosarcoma cell growth by transcription factor, Egr-1, involves down-regulation of Bcl-2. Int J Cancer 1998, 77:880-886.
28. DeWeese TL, Walsh JC, Dillehay LE, Kessis TD, Hedrick L, Cho KR, Nelson WG. Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. Int J Radiat Oncol Biol Phys 1997, 37:145-154.
29. Shai A, Brake T, Somoza C, Lambert PF. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 2007, 67:1626-1635.
30. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
31. Nagasawa H, Keng P, Harley R, Dahlberg W, Little JB. Relationship between gamma-ray-induced G2/M delay and cellular radiosensitivity. Int J Radiat Biol 1994, 66:373-379.
32. Liu Y, Heilman SA, Illanes D, Sluder G, Chen JJ. p53-independent abrogation of a postmitotic checkpoint contributes to human papillomavirus E6-induced polyploidy. Cancer Res 2007, 67:2603-2610.
33. Thomas M, Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998, 17:2943-2954.
34. Thompson DA, Belinsky G, Chang TH, Jones DL, Schlegel R, Munger K. The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. Oncogene 1997, 15:3025-3035.
35. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham GP. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. Cancer 1998, 83:2346-2352.
36. Abdulkarim B, Sabri S, Deutsch E, Chagraoui H, Maggiorella L, Thierry J, Eschwege F, Vainchenker W, Chouaib S, Bourhis J. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002, 21:2334-2346.
37. Gammoh N, Grm HS, Massimi P, Banks L. Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator. J Virol 2006, 80:1787-1797.
38. Gammoh N, Isaacson E, Tomaic V, Jackson DJ, Doorbar J, Banks L. Inhibition of HPV-16 E7 oncogenic activity by HPV-16 E2. Oncogene 2009, 28:2299-2304. Epub 2009 May 4.